ASH 2023 is coming up December 9 – 12, and our team is excited to join the conversation with hematology sponsors and partners like you. Stop by Booth #3352 for a chance (or schedule a meeting here) to speak with PSI experts helping to support hematology-oncology and hemophilia innovators across the globe. Meet our team members who are packing their bags for San Diego.
Director Project Management
Vince serves as a Director and supervisor of Project Management, overseeing PSI’s team of Project Management staff and several studies in oncology and hematology. Vince has been with PSI since December 2019, and is based in Texas. He has over 19 years’ clinical research experience, 15 years of project management experience, and has delivered 20+ oncology studies in both solid tumors and hematology-oncology.
Vince has professional affiliations with the Project Management Institute in the US and has been a certified Project Management Professional since 2012.
Senior Director, Operations
Rhonda Critchlow, Senior Director of Therapeutic Strategy, currently oversees all of PSI’s core indications, and specializes in operational strategy within oncology and radiopharmaceuticals. With over 25 years of research experience, she provides valuable leadership and management working both regionally and globally.
Overseeing the therapeutic strategy department, which includes our Site Support Specialist, Rhonda brings guidance and oversight to specialty vendor management, patient recruitment and retention for our sponsors.
Prior to working at PSI, her experience includes working within oncology research as a Coordinator and Director, CRA, Clinical Trial Manager, Head of Monitoring and Vice President of Early Phase Oncology before joining PSI. Rhonda also has experience working with general radiology and nuclear medicine in large hospital organizations, providing valuable input for clinical development, study management and operational considerations.
Associate Director, Feasibility
Colleen Ring, PhD, Associate Director, Feasibility, has worked in the clinical research industry for the past 12 years. Prior to transitioning to the clinical research field, Colleen was a senior research scientist, specializing in multiple signaling pathways (e.g. TGFb, Tyrosine Kinases, Rho/Rac GTPases) across a broad range of areas, including oncology. As a leader within PSI’s global feasibility team, Colleen specializes in strategy development across multiple therapeutic areas – focusing on aligning a study’s design with top enrolling investigators in the right countries.
Using PSI’s INTELIA platform, a machine-learning-powered system for data-driven feasibility and enrollment forecasting that models and compares hundreds of country and site combinations, their budgets and probability of success, Colleen develops recommendations for optimized enrollment in line with each sponsor’s key objectives.
As an Associate Director, Colleen provides leadership for global feasibility and site identification activities for both pre- and post-award opportunities and projects.